Insider transactions

EDGAR

CytoDyn, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–9 of 9

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-20 Filed 2026-10-20Hoffman Robert E. Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-qualified stock option (right to buy) — underlying Common Stock (2,500,000) — exercise price 0.25
Acquired (A)2,500,0000—2,500,000Direct (D) No
F1, F2
  • F1 This grant was approved by the Company's Compensation Committee on October 16, 2026, pursuant to the Issuer's 2012 Equity Incentive Plan (the Plan).
  • F2 625,000 shares will vest on October 16, 2027, and the balance will vest in equal monthly installments beginning on November 16, 2027 and ending on October 16, 2030, subject to Continuous Service (as the term is defined in the Plan).
Open filing 0001166288-26-000002 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24Blok Tyler Officer: Chief Legal Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-qualified stock option (right to buy) — underlying Common Stock (3,249,794) — exercise price 0.28
Acquired (A)3,249,7940—3,249,794Direct (D) No
F1, F2
  • F1 This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the 2012 Plan).
  • F2 812,448 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030.
Open filing 0001104659-26-033954 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24Ndhlovu Lishomwa C Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-qualified stock option (right to buy) — underlying Common Stock (574,385) — exercise price 0.28
Acquired (A)574,3850—574,385Direct (D) No
F1, F2
  • F1 This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the 2012 Plan).
  • F2 The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.
Open filing 0001104659-26-033961 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24Lalezari Jacob P Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-qualified stock option (right to buy) — underlying Common Stock (4,874,691) — exercise price 0.28
Acquired (A)4,874,6910—4,874,691Direct (D) No
F1, F2
  • F1 This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the 2012 Plan).
  • F2 1,218,672 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030.
Open filing 0001104659-26-033960 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24Urbach Tanya Durkee Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-qualified stock option (right to buy) — underlying Common Stock (574,385) — exercise price 0.28
Acquired (A)574,3850—574,385Direct (D) No
F1, F2
  • F1 This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the 2012 Plan).
  • F2 The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.
Open filing 0001104659-26-033963 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24SIMES STEPHEN M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-qualified stock option (right to buy) — underlying Common Stock (574,385) — exercise price 0.28
Acquired (A)574,3850—574,385Direct (D) No
F1, F2
  • F1 This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the 2012 Plan).
  • F2 The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.
Open filing 0001104659-26-033962 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24Brunke Karen J Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-qualified stock option (right to buy) — underlying Common Stock (574,385) — exercise price 0.28
Acquired (A)574,3850—574,385Direct (D) No
F1, F2
  • F1 This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the 2012 Plan).
  • F2 The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.
Open filing 0001104659-26-033955 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24Dunlap Ryan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-qualified stock option (right to buy) — underlying Common Stock (574,385) — exercise price 0.28
Acquired (A)574,3850—574,385Direct (D) No
F1, F2
  • F1 This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the 2012 Plan).
  • F2 The stock option will vest in 12 approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2026 through March 2027.
Open filing 0001104659-26-033957 Read from the filing’s XML Dispute this row
2026-03-20 Filed 2026-03-24Hoffman Robert E. Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Non-qualified stock option (right to buy) — underlying Common Stock (4,874,691) — exercise price 0.28
Acquired (A)4,874,6910—4,874,691Direct (D) No
F1, F2
  • F1 This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the 2012 Plan).
  • F2 1,218,672 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030.
Open filing 0001104659-26-033958 Read from the filing’s XML Dispute this row

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

Latest reported holdings
Reporting ownerSecurityShares owned afterDirect or indirectSource
Blok Tyler Officer: Chief Legal OfficerNon-qualified stock option (right to buy) Derivative security · underlying Common Stock3,249,794D As of 2026-03-20 Open filing 4
Brunke Karen J DirectorNon-qualified stock option (right to buy) Derivative security · underlying Common Stock574,385D As of 2026-03-20 Open filing 4
Dunlap Ryan DirectorNon-qualified stock option (right to buy) Derivative security · underlying Common Stock574,385D As of 2026-03-20 Open filing 4
Hoffman Robert E. Officer: Chief Executive OfficerNon-qualified stock option (right to buy) Derivative security · underlying Common Stock2,500,000D As of 2026-10-20 Open filing 4
Lalezari Jacob P Officer: Chief Executive OfficerNon-qualified stock option (right to buy) Derivative security · underlying Common Stock4,874,691D As of 2026-03-20 Open filing 4
Ndhlovu Lishomwa C DirectorNon-qualified stock option (right to buy) Derivative security · underlying Common Stock574,385D As of 2026-03-20 Open filing 4
SIMES STEPHEN M DirectorNon-qualified stock option (right to buy) Derivative security · underlying Common Stock574,385D As of 2026-03-20 Open filing 4
Urbach Tanya Durkee DirectorNon-qualified stock option (right to buy) Derivative security · underlying Common Stock574,385D As of 2026-03-20 Open filing 4

Joint filers each report the same shares, so rows are not added together.

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–5 of 5

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Williams Jones Wealth Management, LLC. 64,001 SH13,120 dollarsHigher by 19,000 Prior quarter: 45,001Open filing 0001104659-26-123101 Filed 2026-11-05 Dispute this row
HORIZON FINANCIAL SERVICES, LLC Partly reported under another manager18,200 SH3,731 dollarsUnchanged Prior quarter: 18,200Open filing 0001674020-26-000005 Filed 2026-11-04 Dispute this row
Ancora Advisors LLC Partly reported under another manager9,488 SH1,945 dollarsUnchanged Prior quarter: 9,488Open filing 0001446114-26-000020 Filed 2026-11-17 Dispute this row
CAZ INVESTMENTS LP 4,000 SH820 dollarsUnchanged Prior quarter: 4,000Open filing 0001159363-26-000014 Filed 2026-11-16 Dispute this row
Benson Wealth Management INC 198 SH41 dollarsNot in the prior quarter’s filings read Open filing 0002109863-26-000005 Filed 2026-11-12 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • DIVERSIFIED TRUST CO 45,790 SH
  • Next Capital Management LLC 25,000 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text; they are read only when their rows add up to the totals the filer states.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Institutional ownership reported on Form 13F

No percent is shown: the cover-page share count is not available for this company.

  • The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
  • Neither includes holders that do not file Form 13F, or managers below the filing threshold.
Quarter-by-quarter 13F holders
QuarterManagers holdingShares, at leastShares, at mostFilings read
2026-09-30 568,19995,8878,935
2026-06-30 6119,791147,4799,178
2026-03-31 8120,291307,9799,173
2025-12-31 8172,291359,9799,222
2025-09-30 10231,662419,3508,469
2025-06-30 10286,198313,8868,516
2025-03-31 10240,741268,4298,518
2024-12-31 10196,241275,4298,580

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Paul A. Rosenbaum Common Stock, $0.001 par value per share0.211,300,000— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Anthony Caracciolo Common Stock, $0.001 par value per share0.221,368,000— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Arthur L. Wilmes Common Stock, $0.001 par value per share0.0190,000— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Glenn Eisenberg Common Stock, $0.001 par value per share0.331,994,536— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Jeffrey Paul Beaty Common Stock, $0.001 par value per share0.15888,888— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Allen Gabriel Common Stock, $0.001 par value per share0.271,659,465— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Judson Longaker Common Stock, $0.001 par value per share0.07445,000— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Steve Dalal Common Stock, $0.001 par value per share0.09548,125— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Jeffrey D. Weiner Common Stock, $0.001 par value per share0.09574,657— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Frederick J. Axelberd Common Stock, $0.001 par value per share0.02121,500— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Yaron Okun Common Stock, $0.001 par value per share0.291,795,529— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Jack Chitayat Common Stock, $0.001 par value per share0.744,530,400— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Arlyn J. Bossenbrook Common Stock, $0.001 par value per share0.04226,436— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Paul Hydok Common Stock, $0.001 par value per share0.201,232,000— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Charles M. Johnson Jr. Common Stock, $0.001 par value per share0.07425,172— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Jonathan Hartley Common Stock, $0.001 par value per share0.07450,000— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Brendan Thorson Common Stock, $0.001 par value per share0.10635,100— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Joe Rector Common Stock, $0.001 par value per share0.10618,800— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Francesco Tosco Common Stock, $0.001 par value per share0.10638,000— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
William M. Rawson Common Stock, $0.001 par value per share0.442,690,125— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Veronica Marano Common Stock, $0.001 par value per share0.08503,076— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Dr. Richard G. Pestell Common Stock, $0.001 par value per share1.8711,435,728— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Peter Christopher Caputo Common Stock, $0.001 par value per share0.07401,581— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Antonio Parisi Common Stock, $0.001 par value per share0.05288,500— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Thomas C. Mollick Common Stock, $0.001 par value per share1.69,814,945— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Thomas J. Errico M.D. Common Stock, $0.001 par value per share0.412,508,705— Filed 2021-06-08SC 13D/AAmendment 1Read from the cover page textOpen filing 0001104659-21-078265 Dispute this row
Paul A. Rosenbaum Common Stock, $0.001 par value per share0.211,300,000— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Anthony Caracciolo Common Stock, $0.001 par value per share0.221,368,000— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Arthur L. Wilmes Common Stock, $0.001 par value per share0.0190,000— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Glenn Eisenberg Common Stock, $0.001 par value per share0.331,994,536— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Jeffrey Paul Beaty Common Stock, $0.001 par value per share0.14850,000— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Allen Gabriel Common Stock, $0.001 par value per share0.271,659,465— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Judson Longaker Common Stock, $0.001 par value per share0.07445,000— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Steve Dalal Common Stock, $0.001 par value per share0.09548,125— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Jeffrey D. Weiner Common Stock, $0.001 par value per share0.09574,657— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Frederick J. Axelberd Common Stock, $0.001 par value per share0.02121,500— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Yaron Okun Common Stock, $0.001 par value per share0.291,795,529— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Jack Chitayat Common Stock, $0.001 par value per share0.744,530,400— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Arlyn J. Bossenbrook Common Stock, $0.001 par value per share0.04225,681— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Paul Hydok Common Stock, $0.001 par value per share0.201,232,000— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Charles M. Johnson Jr. Common Stock, $0.001 par value per share0.07425,172— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Jonathan Hartley Common Stock, $0.001 par value per share0.07450,000— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Brendan Thorson Common Stock, $0.001 par value per share0.10635,100— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Joe Rector Common Stock, $0.001 par value per share0.10618,800— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Francesco Tosco Common Stock, $0.001 par value per share0.10638,000— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
William M. Rawson Common Stock, $0.001 par value per share0.442,690,125— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Veronica Marano Common Stock, $0.001 par value per share0.08503,076— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Dr. Richard Pestell Common Stock, $0.001 par value per share1.8711,435,728— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Peter Christopher Caputo Common Stock, $0.001 par value per share0.07401,581— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row
Antonio Parisi Common Stock, $0.001 par value per share0.05288,500— Filed 2021-05-24SC 13DRead from the cover page textOpen filing 0001104659-21-071328 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

3,092,627 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015246,723
2016246,472
2017244,814
2018245,575
2019238,619
2020249,093
2021274,850
2022257,922
2023253,676
2024261,106
2025235,525
2026263,830

Filings made before the SEC required XML are listed, not extracted.

Back to CytoDyn, Inc.